

DAFTAR PUSTAKA

- Ahn, S. and Lee, Y.S. 2012, Predictive factors for poor prognosis febrile neutropenia, *Curr Opin Oncol*, **24**: 376-380 cit. Yapici, O. dkk. 2016, Evaluation of Febrile Neutropenic Episodes in Adult Patients with Solid Tumors, *Molecular and Clinical Oncology*, **4**: 379-382.
- Alshukairi, A., Alserehi, H., El-Saed, A., Kelta, M., Rehman, J.U., Khan, F.A., dkk. 2016, A de-escalation protocol for febrile neutropenia cases and its impact on carbapenem resistance: A retrospective, quasi-experimental single-center study, *Journal of Infection and Public Health*, **9**: 443–451.
- Baden, L.R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E.R., Freifeld, A.G., dkk. 2013, NCCN Clinical Practice Guideline in Oncology: Prevention and Treatment of Cancer-Related Infections, *National Comprehensive Cancer Network, Inc.*, **I**: 11-25.
- Bauer, A. L. 2008, *Applied Clinical Pharmacokinetics, Second Edition*, Departments of Pharmacy and Laboratory Medicine Schools of Pharmacy and Medicine University of Washington, Seattle, Washington.
- Bernardi, M. 2012, Human albumin in the management of complications of liver cirrhosis. *Crit Care*, **16**: 211 cit. Serlemitsos, D. M., Ellington, K., Akalu, A., and Kimberly, N.U. 2017, Should Medications be Coadministered with Albumin in Hypoalbuminemic Patients, *J Pharma Care Health Sys*, **4** (1): 1-4.
- Burke, M.D. 2016, Neutropenic Fever Empiric Therapy, *Medscape*, 11 Februari 2016.
- Caggiano, V., Weiss, R.V., Rickert, T.S. & Linde-Zwirble, W.T. 2005, Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy, *Cancer*, **103**: 1916–1924.
- Carratala J., Roson B., Fernandez-Sevilla A., dkk. 1998, Bacteremic pneumonia in and neutropenic patients with cancer: causes, empirical antibiotik therapy, and outcome, *Arch Intern Med*, **158**:868–72.
- Cattaneo C., Quaresmini G., Casari S., dkk. 2008, Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant *Escherichia coli* among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution, *J Antimicrob Chemother*, **61**:721–8.
- Crumley, A.B., Stuart, R.C., McKernan, M., McMillan, D.C. 2010, Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer, *World J Surg*, **34**: 2393-2398 cit. Serlemitsos, D. M., Ellington, K., Akalu, A., and Kimberly, N.U. 2017, Should Medications be Coadministered with Albumin in Hypoalbuminemic Patients, *J Pharma Care Health Sys*, **4** (1): 1-4.
- Dahlan, M. 2013, *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*, 3rd ed. Salemba Medika, Jakarta.

- de Naurois, J., Novitzky-Basso, I., Gill, M.J., Marti, F.M., Cullen, M.H., Roila, F., dkk. 2010, Management of febrile neutropenia: ESMO Clinical Practice Guidelines, *Annals of Oncology*, **21**: v252–v256.
- Di Fiore, F., Leclaire, S., Pop, D., Rigal, O., Hamidou, H., Paillot, B., dkk. 2007, Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer, *Am J Gastroenterol*, **102** (11): 2557–63.
- Drusano, G.L., Joshi, J., Forrest, A., Ruxer, R., Standiford, H., Leslie, dkk. 1985, Pharmacokinetics of ceftazidime, alone or combination with piperacillin or tobramycin, in the sera of cancer patient, *Antimicrob. Agents Chemother.* **27** (4): 605-607.
- Flowers, C.R., Seidenfeld, J., Bow, EJ, Karten, C., Gleason, C., Hawley, D.K., dkk. 2013, Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline, *J Clin Oncol*, **31**:794–810.
- Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., dkk. 2011, Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America, *Clinical Infectious Diseases*, **52**: e56–e93 cit.
- Villafuerte-Gutierrez, P., Villalon, L., Losa, J.E., dan Henriquez-Camacho, C. 2014, Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update, *Hindawi Publishing Corporation Advances in Hematology*, **2014**: 1-10.
- Furno, P., Bucaneve, G., Del Favero, A. 2002, Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis, *Lancet Infect Dis*, **2**:231–242 cit.
- Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., dkk. 2016, Management of Febrile Neutropenia: ESMO Clinical, *Annals of Oncology*, **27**:111–118.
- Glasmacher, A., Von Lilienfeld-Toal, M., Schulte, S. 2005, An evidence based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients, *Clin Microbiol Infect* **11**, **5**: 17-23 cit.
- Yapici, O. dkk. 2016, Evaluation of Febrile Neutropenic Episodes in Adult Patients with Solid Tumors, *Molecular and Clinical Oncology*, **4**: 379-382.
- González-Barca, E., Fernández-Sevilla, A., Carratalá, J., Salar, A., Peris J., Grañena, A., dkk. 1999, Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia, *Eur J Clin Microbiol Infect Dis*, **18**: 539-544 cit.
- Yapici, O. dkk. 2016, Evaluation of Febrile Neutropenic Episodes in Adult Patients with Solid Tumors, *Molecular and Clinical Oncology*, **4**: 379-382.
- Gupta, D., & Lis, C.G. 2010, Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature, *Nutrition Journal, Biomed Central*, **9** (69): 1-16.
- Gupta, D., Lis, C.G., Vashi, P.G., Lammersfeld, C.A. 2010, Impact of improved nutritional status on survival in ovarian cancer, *Support Care Cancer*, **8** (3): 373–81.

- Hakim, L. 2014, *Farmakokinetik Klinis, Seri Farmasi Klinis*, Bursa Ilmu, Yogyakarta. 66-69.
- He, L., Zhou, C., Zhao, S., Weng, H., & Yang, G. 2015, Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China, *Anti-Cancer Drugs*, **26** (3): 359-362.
- Hindler, J.F. dan Stelling, J. 2007, Analysis and Presentation of Cumulative Antibiograms: A New Consensus Guideline from the Clinical and Laboratory Standards Institute, *Clinical Infectious Diseases*, **44**: 867-873.
- Hogg. R.J., Ronald, J.P., Dawn, M. 2000, Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE), *Pediatrics*, 105: 1242-1249 cit. Serlemitsos, D. M., Ellington, K., Akalu, A., and Kimberly, N.U. 2017, Should Medications be Coadministered with Albumin in Hypoalbuminemic Patients, *J Pharma Care Health Sys*, **4** (1): 1-4.
- Hughes W.T., Armstrong D., Bodey G.P., dkk. 2002, Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, *Clin Infect Dis*, **34**:730–51.
- Karthaus, M., Wolf, H.H, Kämpfe, D., Egerer, G., Ritter, J., Peters, G. dkk. 1998, Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia, *MEDLINE*, **44** (5):343-54.
- Kementerian Kesehatan. 2011, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/Menkes/Per/XII/2011, tentang pedoman Umum Penggunaan Antibiotik*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan. 2015, *Peraturan Menteri Kesehatan Republik Indonesia No. 8 Tahun 2015 tentang Program Pengendalian Resistensi Antibiotik*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Klastersky J. 2004, Management of Fever in Neutropenic Patients with Different Risks of Complications, *Clin Infect Dis*, **39** (1):S32–7.
- Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Apro, M., dkk. 2016, Management of Febrile Neutropaenia: ESMO Clinical, *Annals of Oncology*, **27**:111–118.
- Kosten T. 2012, *Infection in Patients with Cancer*, In: *Lango Fauci Kasper, Harrison's Principles of Internal Medicine*, 18th edition, Mcgraw Hill, United States of America.
- Kroll, A.L., Corrigan, P.A., Patel, S., dan Hawks, K.G. 2016, Evaluation of empiric antibiotic de-escalation in febrile neutropenia, *Journal of Oncology Pharmacy Practice*, **22**: 696–701.
- Kuderer, N.M., Dale, D.C., Crawford, J., Cosler, L.E., dan Lyman, G.H. 2006, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, *Cancer*, **106**: 2258–2266.
- Lacy, C.H., Armstrong, L.L., Goldman, M.P., Lance, L.L. (ed). 2012, *Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals 20th edition*, Lexi –Comp, Ohio.

- Lamoth, F., Buclin, T., Pascual, A., Calandra, T., dan Marchetti, O. 2009, Imipenem underdosing as a cause of persistent neutropenic fever? *Journal of Antimicrobial Chemotherapy*, **64**: 665–667.
- Leekha, S., Terrell, C.L., dan Edson, R.S. 2011, General Principles of Antimicrobial Therapy, *Mayo Clinic Proceedings*, **86**: 156–167.
- L. Leibovici, M. Paul, M. Cullen dkk. 2006, Antibiotik prophylaxis in neutropenic patients: new evidence, practical decisions, *Cancer*, **8**:1743–1751.
- López-Pousa, A., Rifà, J., Casas de Tejerina, A., González-Larriba, J.L., Iglesias, C., Gasquet, J.A. & Carrato, A. 2010, Risk assessment model for first-cycle chemotherapy induced neutropenia in patients with solid tumours, *European Journal of Cancer Care*, **19**: 648–655.
- Lortholary O., Lefort A., Tod M., Chomat AM., Darras-Joly C., Cordonnier C. 2008, Pharmacodynamics and Pharmacokinetics of Antibacterial Drugs in the Management of Febrile Neutropenia, *Lancet Infect Dis*, **8**:612-620.
- Lyman, G.H., Morrison, V.A., Dale, D.C., dkk. 2003, Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy, *Leuk Lymphoma*, **44**:2069-2076 cit. Lyman, G. H. & Rolston, K. V. I. 2010, How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy, *Journal of Oncology Practice*, **6** (3): 149-152.
- Lyman, G. H. & Rolston, K. V. I. 2010, How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy, *Journal of Oncology Practice*, **6** (3): 149-152.
- Meunier F., Lukan C. 2008, The First European Conference on Infections in Leukaemia - ECIL1: a Current Perspective, *Eur J Cancer*, **44**:2112-2117
- Morris P.G., Hassan T., McNamara M., dkk. 2008, Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern, *Support Care Cancer*, **16**:1085–8.
- Mouton J.W., Touzw D.J., Horrevorts A.M., Vinks A.A. 2000, Comparative Pharmacokinetics of the Carbapenems: Clinical Implications, *Clin Pharmacokinet*, **39**:185-201.
- Numeroso, F., Barilli, A.L., Delsignore, R. 2008, Prevalence and significance of hypoalbuminemia in an internal medicine department, *Eur J Intern Med*, **19** (8): 587–91.
- Paik, S., Senty, L., Das, S., Noe, J.C., Munro, C.L., and Kitten, T. 2005, Identification of Virulence Determinants for Endocarditis in *Streptococcus Sanguinis* by Signature Tagged Mutagenesis, *American Society for Microbiology Journal*, **73**(9): 6064-6074.
- Paul, M., Yahav, D., Fraser, A., dan Leibovici, L. 2006, Empirical antibiotik monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials, *The Journal of Antimicrobial Chemotherapy*, **57**: 176–189.
- Quan, D.J. dan Aweeka, F.T. 2009. Dosing of Drugs in Renal Failure, dalam: Koda Kimble, M.A. (ED.), *Applied Therapeutics The Clinical Use of Drugs*. Lippincott Williams & Wilkins, Philadelphia, hal. 811-826.

- Ramphal R. 2004, Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens, *Clin Infect Dis*, **39** (Suppl 1):S25–31
- Ranuhardy D. 2011, *Neutropeni Febril pada Kanker, Buku Ajar Ilmu Penyakit Dalam*, Edisi V, Interna Publishing, Jakarta.
- Restinia, M., Lucida, H., dan Gillani, S.W. 2010, Longitudinal clinical evaluation of antibiotic use among patients with infecton, *International Journal of Pharmacy & Life Sciences*, **3**: 1935–1945.
- Rosa, R.G., Goldani, L.Z., Dos, S.R. 2014, Risk factors for multidrug-resistant bacteremia inhospitalized cancer patients with febrile neutropenia: a cohort study, *Am J Infect Control*, **42**:74–6.
- Rosenberg P.S., Alter B.P., Bolyard A.A., dkk. 2006, The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy, *Blood*, **107**:4628–35
- Rolston, K.V.I. 2005, Challenges in the Treatment of Infections Caused by Gram-Positive and Gram-Negative Bacteria in Patients with Cancer and Neutropenia, *Clinical Infectious Diseases*, **40**: S246–S252.
- Rybak, M.J., Lomaestro, B.M., Rotscahfer, J.C., Moellering, R.C., Craig, W.A., Billeter, M., dkk. 2009, Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, *Clinical Infectious Diseases*, **49**: 325–327.
- Seo, S.H., Kim, S-E., Kang, Y-K., Ryoo, B-Y., Ryu, M-H., Jeong, J.H., dkk. 2016, Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients, *BMC Cancer*, **16**: 1-9.
- Shargel, L., Wu-Pong, S., Yu, A.B.C. 2005, *Applied Biopharmaceutics and Pharmacokinetics*, 5th edition, McGraw-Hill, New York.
- Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L, dkk. 2006, Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, *Journal of Clinical Oncology*, **24**: 3187–3205.
- Tavill, A.S. 1971, Protein-losing enteropathy, *J Clin Path*, **3**:45-54 cit. Serleimitsos, D. M., Ellington, K., Akalu, A., and Kimberly, N.U. 2017, Should Medications be Coadministered with Albumin in Hypoalbuminemic Patients, *J Pharma Care Health Sys*, **4** (1): 1-4.
- Theuretzbacher, U. 2012, Pharmacokinetic and Pharmacodynamis Issues for Antimicrobial Therapy in Patients with Cancer, *CID*, **54**: 1785-1793.
- Ulldemolins, M., Roberts, J.A., Rello, J., Paterson, D.L., Lipman, J. 2011, *Clinical Pharmacokinetic, Pubmed*, **50** (2): 99-110.
- Villafuerte-Gutierrez, P., Villalon, L., Losa, J.E., dan Henriquez-Camacho, C. 2014, Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update, *Hindawi Publishing Corporation Advances in Hematology*, 1-9.
- Weinstock D.M., Conlon M., Iovino C., dkk. 2007, Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early

- after allogeneic hematopoietic stem cell transplant, *Biol Blood Marrow Transplant*, **13**:615–21.
- WHO. 2011, 'Step-by-step approach for development and implementation of hospital and antibiotic policy and standard treatment guidelines', SEARO.URL:http://www.searo.who.int/entity/antimicrobial_resistance/documents/SEA_HML_414/en/ (diakses tanggal 2/1/2016)
- Winter, M.E. 1994, *Basic Clinical Pharmacokinetics*, 3rd ed., Applied Therapeutics, Inc., Vancouver.
- Wisplinghoff H, Seifert H, Wenzel RP, dkk. 2003, Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States, *Clin Infect Dis*, **36**:1103–10
- Yapici, O. dkk. 2016, Evaluation of Febrile Neutropenic Episodes in Adult Patients with Solid Tumors, *Molecular and Clinical Oncology*, **4**: 379-382.
- Zhai, W., Zhang, X., Wei, J., Deng, Q., Dong, X., Zhang, X., dkk. 2015, A Prospective Observational Study of Antibiotic Therapy in Febrile Neutropenia Patients with Hematological Malignancies from Multiple centers in Northeast China, *International Journal of Infectious Diseases*, **37**: 97–103.
- Zinner SH. 1999, Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria, *Clin Infect Dis*, **29**:490–4.